van Deutekom J C, Floyd S S, Booth D K, Oligino T, Krisky D, Marconi P, Glorioso J C, Huard J
Department of Orthopaedic Surgery, Children's Hospital, 4151 Rangos Research Center, Pittsburgh, PA 15213, USA.
Neuromuscul Disord. 1998 May;8(3-4):135-48. doi: 10.1016/s0960-8966(98)00019-4.
Different viral vectors have been analyzed as gene delivery vehicles to skeletal muscle for potentially therapeutic purposes. In this review, we evaluate the application of retroviral, adenoviral, and herpes simplex viral vectors to deliver genes to skeletal muscle and focus on the dramatic loss of viral transduction detected throughout muscle maturation. Recent results suggested that there are several factors involved in the reduced viral transducibility of mature skeletal muscle: muscle cells become post-mitotic in an early stage, the extracellular matrix develops into a physical barrier, and a loss of myoblast mediation occurs since myoblasts progressively become quiescent. Approaches to improve viral gene delivery to mature skeletal muscle may include the use of particular enzymes to increase the permeability of the extracellular matrix, the pre-treatment of the muscle with a myonecrotic agent to induce myoblast mediation, or the application of the myoblast-mediated ex vivo gene transfer.
